Matthias Bodenstedt is CFO at MoonLake Immunotherapeutics (MLTX). They have made 1 open-market trade across 1 company since 2023, most recently 2026-06-22.
CIK 0001920545
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $198K since 2025, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MLTX | 1,115,435 | $10.6M |
Shares reported on the most recent Form 4, priced at the 2026-06-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MLTX | SELL · 10b5-1 | 2026-06-22 | 2026-06-23 | $22.04 | $862K | -2.4% | -0.1% | -35.4% |
| MLTX | SELL · 10b5-1 | 2026-06-17 | 2026-06-18 | $19.67 | $352K | -4.3% | -4.9% | -37.6% |
| MLTX | SELL · 10b5-1 | 2026-05-11 | 2026-05-13 | $20.02 | $273K | -0.6% | +1.9% | -9.4% |
| MLTX | SELL · 10b5-1 | 2026-04-14 | 2026-04-16 | $19.56 | $47K | -8.9% | -10.1% | +9.0% |
| MLTX | SELL · 10b5-1 | 2026-04-09 | 2026-04-10 | $18.95 | $1.7M | -3.5% | +5.7% | +11.7% |
| MLTX | BUY | 2025-10-08 | 2025-10-09 | $9.09 | $198K | -3.6% | +13.9% | +18.8% |
| MLTX | SELL · 10b5-1 | 2023-12-19 | 2023-12-21 | $59.17 | $11.8M | -3.7% | -6.1% | -16.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.